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Abstract.  A  recently described splice variant of CD44 
expressed in metastasizing  cell lines of rat tumors has 
been shown to confer metastatic potential to a non- 
metastasizing  rat pancreatic carcinoma cell line and to 
non-metastasizing  sarcoma cells. Homologues of this 
variant as well as several other CIM4 splice variants 
are also expressed at the RNA level in human carci- 
noma cell lines from lung,  breast,  and colon, and in 
immortalized keratinocytes. 
Using antibodies raised against a bacterial fusion 
protein encoded by variant CD44 sequences, we studied 
the expression of variant CD44 glycoproteins in nor- 
mal human tissues and in colorectal neoplasia. Expres- 
sion of CD44 variant proteins in normal human tissues 
was readily found on several epithelial tissues includ- 
ing the squamous epithelia of the epidermis,  tonsils, 
and pharynx,  and the glandular epithelium of the pan- 
creatic ducts, but was largely absent from other epithe- 
lia and from most non-epithelial cells and tissues. In 
human colorectal neoplasia CD44 variant proteins, in- 
eluding homologues of those which confer metastatic 
ability to rat tumors, were found on all invasive carci- 
nomas and carcinoma metastases.  Interestingly,  focal 
expression was also observed in adenomatous polyps, 
expression being related to areas of dysplasia. The dis- 
tribution of the CD44 variants in human tissues sug- 
gests that they play a role in a few restricted differew 
tiation pathways and that in colorectal tumors one of 
these pathways has been reactivated.  The finding that 
metastasis-related variants are already expressed at a 
relatively early stage in colorectal carcinogenesis and 
tumor progression, i.e.,  in adenomatous polyps, sug- 
gests the existence of a yet unknown selective advan- 
tage linked to CD44 variant expression.  The continued 
expression in metastases would be compatible with a 
role in the metastatic process. 
T 
UMOR metastasis is the principal cause of death  for 
cancer patients.  A subset of parental tumor cells ac- 
quire metastatic properties, presumably through a se- 
ries of genetic alterations  (Nicolson 1987; Hart et al., 1989). 
As a result of this process of tumor progression, carcinoma 
ceils detach from the primary tumor, penetrate the basement 
membrane into the connective  tissue and invade  adjacent 
structures including  lymph and blood vessels.  The tumor 
cells are subsequently transported to sites of metastatic out- 
growth via lymph or blood. This dissemination process obvi- 
ously requires a complex series of interactions  of tumor cells 
with extracellular  matrix components and with other cells 
probably involving adhesion receptors, proteolytic enzymes, 
growth factors,  and growth factor receptors. 
In an analysis of the metastatic properties of rat carcinoma 
cells,  antibodies were raised that recognize  antigens  exclu- 
sively expressed in the metastasizing  clonal variants of these 
tumors (Matzku et al., 1989). Using one of these antibodies, 
we have isolated eDNA sequences that encode splice variants 
of CD44 (Giinthert et al., 1991; Rudy, W., M. Hofmann, R. 
Schwartz-Albiez,  M. Z611er, K.-H. Heider, H. Ponta, and P. 
Herrlich, manuscript submitted for publication).  The metas- 
tasis-associated epitope is part of an enlarged  extracellular 
region that is not present in standard  CD44. Several metas- 
tasizing  rat tumor cell clones express a heterogeneous set 
of splice variants.  Coinjection of variant-specific  mAb with 
the metastasizing  cells provoked retardation  and even com- 
plete block of metastatic spread in vivo (Reber et al., 1990; 
Seiter, S., R. Arch, D. Komitowski, M. Hofmann, H. Ponta, 
P. Herrlich, S. Matzku, and M. Z611er, manuscript submit- 
ted for publication).  Moreover, overexpression of either one 
of two of the metastasis-specific  variants  in non-metasta- 
sizing tumor cell lines conferred metastatic abilities on them 
(Giinthert et al., 1991; Rudy, W., M. Hofmann, R. Schwartz- 
Albiez, M. Z611er, K.-H. Heider, H. Ponta, and P. Herrlich, 
manuscript  submitted  for publication).  Hence, these splice 
variants of CD44 are causally involved in the metastatic pro- 
cess.  Homologues of the rat CD44 splice variants are also 
expressed at the RNA level in human carcinoma lines from 
lung, breast, and colon (Hofmann et al., 1991). Using anti- 
bodies raised against a fusion protein that carries sequences 
of the human variant domains,  we have now studied the ex- 
pression of CD44 variant glycoproteins in human colorectal 
neoplasia  and normal human tissues.  While normal colon 
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The expression is acquired early in tumor progression dur- 
ing the adenomatous polyp stage. According to PCR data, 
one specific CD44 variant is expressed  predominantly. The 
data establish the variant CD44 exon sequences as tumor 
progression marker in human colorectal cancer. 
Materials and Methods 
Cell Culture 
The two cell lines Colo 205 and Colo 320 were received from the American 
Culture Collection  (Rockwille,  MD); all  other cell lines and their cul- 
ture  conditions have been described previously (t'Iofn'~nn  et al., 1991). 
Cloning of  pGEX Fusion  Proteins 
The whole variant region of the HPKH-type CD44v (Hofmann et al., 1991; 
and see Fig. 1) was cloned from cDNA via PCR amplification. The two PCR 
primers  (5'-Ch~_GCCAAATGAAGAAAATG-3',  and  5"TGA- 
TAAGGAACGATTC~.CATTAGAGTIUC~-3~  correspond  to positions 25 
to 52 and positions 1013 to 984, respectively, of  the LCLC97 variant region 
as described in Hofmann et al. (1991). In addition they carry an EcoRI rec- 
ognition site at the 5' end that was used to clone the PCR product directly 
into the pGEX-2T vector (Smith and Johnson,  1988). The resulting con- 
struct (pGEX CD44v HPKII ffi v3 to vl0) codes for a fusion protein of,~70 
kD. 
To obtain subclones of the variant region that could later be used for 
~ty  purification,  fraements comprising DI (v3) and Din (v6~ v7) (see 
Fig.  1) were cloned using appropriate  restriction  sites. Fusion protein DI 
contains the CD44 sequence from position 744 (Stamenkevic et aL, 1989) 
to position 142 of  variant CD44 (Hofmann et al., 1991), and fusion protein 
Dig the variant sequence from positions 378 to 638 (Hofmann ct al., 1991). 
Both fragments were cloned into the pGEX vector system. 
Immunization and Purification  of  Antisera 
New Zealand white rabbits were immunized ao~ording to stand~d proce- 
dures. 200/tg of affinity purified fusion protein derived from pGEX CD44v 
HPKII (v3 to vl0) was injected s.c. together  with 400 #1 Freund's incom- 
plete adjuvant four times within 9 wk. 
To ren~ve antibodies directed ~inRt the glutathione transferase part of 
the fnsion  protein, the pGEX-2T gkRathione ~rase  fragment was cou- 
pled to CNBr-a~tivated Sephamse 4B (Pharmacm Fine Chemi~s, Piscata- 
way, NJ), according to the manufacturers instructions.  The serum was ap- 
plied to the column three consecutive times, the flow through was collected 
and loaded omo affinity columns to which either CD44v HPKII (v3 to vl0), 
DI (v3), or Dig (v6, r  was coupled. After  washing the colnmnn with coup- 
ling buffer  (0.1 M  NaHCO3, pH 8, 0.5  M  NaCl), specific antibodies  were 
eluted  with I00 mM  glycine,  pH 2.5,  and the  relative  antibody  concentra- 
tion  was measured in an ELISA assay.  For the ELISA the fusion  protein 
CD44v HPKII (v3 to vl0) was coated onto a 96-well microtiter plate in ex- 
cess. The wells were then incubated with several antibody dilutions for 2 h, 
washed  with  PBS,  and  incubated with alkaline  phosphatase-coupled 
anti-rabbit IgG. The conversion ofp-nitrophenyl-phosphate  was measured 
at 405 nm in an ELISA reader.  For Western blot analysis and immuno- 
histochemistry  equal relative concentrations  of each antibody were used. 
mAbs 
The mAb NKI-P1 is directed against the standard form of CD44 (Pals et 
al., 1989a). The mAb pAblS01 directed against p53 was purchased from 
Cambridge Research Biochemicals Ltd., Northwich,  UK. 
Western Blot Analysis 
Cells were lysed  by  sonication  and  boiling in SDS  gel sample  buffer 
(Laemmli, 1970).  Frozen tumor material was pulverized under liquid nitro- 
gen, taken up in gel sample buffer and sonicated. Proteins were electropho- 
retically resolved on 6% reducing SDS polyacrylamide (Laemmii,  1970). 
Bacterial fusion proteins were taken up in gel sample buffer, boiled,  and 
resolved on 10% SDS polyacrylamide.  Proteins were transferred to poly- 
vinylidene difluoride  membranes  (Millipore  Continental  Water Systems, 
Bedford,  MA) using a transblot  apparatus  (Bio-Rad Laboratories,  Cam- 
bridge, MA). Nonspecific interactions were blocked with PBS containing 
10% dry milk, Then the membranes  were incubated at room temperature 
with  the polyclonal  antibodies,  followed by  alkaline  phosphatase-con- 
jugated goat anti-rabbit IgG (Amersham Corp., Arlington Heights, IL), for 
1-h each. After each individual antibody incubation, the membranes were 
washed with PBS containing 0.3% Tween 20 (Sigma Chemical Co.). Sig- 
nals were developed with the enhanced chemoluminescent system (Amer- 
sham Corp.). 
Tissues 
Normal and  pathological  tissues  were  selected  from  the files of the Depart- 
ment of Pathology,  Academic Medical Center, University of Amsterdam, 
The Netherlands,  and tested  for  expression  of  CD44, variant  CIM4, and 
p53, employing the  mono- and polyclonal  antibodies  described  above.  All 
normal tissues were obtained as a corollary of standard surgical procedures. 
Colorectal adenocarcinomas (n ffi 17), adenomatous polyps (n -- 17) and 
colorectal carcinoma metastases (n =  8) were obtained from a total of 33 
patients. Of these, six patients (four carcinomas  and six polyps) suffered 
from familial polyposis coti, other cases being sporadic. Of  the primary car- 
cinomas two were Dukes' A, six were Dukes' B, five were Dukes' C, and 
four were Dukes' D (Dukes,  1932). Histologically, the degree of dysplasia 
in the polyps ranged from mild to severe, while the histological grade of 
the mmo~ ranged from well differentiated  to poorly differentiated. 
Immunohistochemistry 
Frozen sections were fixed in methanol for 10 vain, washed in PBS, and 
preincubated with normal goat serum (10% in PBS). ARer three washes in 
PBS the sections were incubated with the primary  antibody (in PBS/I% 
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Figure 1. (A) Schematical rep- 
resentation  of  HPKII-ty~ 
CD44v. Boxes v3 to vl0 indi- 
cate exons that are not spliced 
out in the immortalized kera- 
tinocytes  (HPKI~.  Hatched 
boxes  indicate  standard  type 
CD44  sequences.  (B)  Sche- 
matical representation of bac- 
terially expressed fusion pro- 
tein encoded by pGEX CD44v 
HPKII (v3 to vl0).  Location 
of the  subcloned  regions  DI 
(v3) and DHI (v3, v'/) is indi- 
cated. 
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proteins with different polyclonal CD44v-specific antibodies. Rep- 
lica gel resolutions (10%  SDS polyacrylamide) are shown all of 
which carry the following order of the fusion proteins: DI (lane 1), 
DIN (lane 2), CD44v (v3 to vl0) (lane 3), and glutathione trans- 
ferase (lane 4). The figure shows the reaction of the fusion proteins 
with anti-DI (A), anti-Dl/I (B), and anti-CIM4v (v3 to vl0) (C). 
In D the Coomassie-stained SDS gel is shown. All antibodies used 
had been affinity-purified as described in Materials and Methods. 
Note that the fusion proteins migrate abnormally in the SDS gel 
(the DI peptide is 33 kD in size but runs at an apparent molecular 
weight of 42 kD). 
BSA) for 1 h. Before incubating with the secondary biotinylated antibody 
for 30 rain (anti-mouse and anti-rabbit F(ab')2; Dako Corp.,  Santa Bar- 
bara, CA) endogenous peroxidases were blocked by 0.3 % 1-1202 in metha- 
nol. As an enzyme for color development  horseradish-peroxidase was used, 
which had been coupled to the biotine via a streptavidine-biotin-peroxidase 
complex (Dako Corp.).  After incubation for 30 rnin the sections were in- 
cubated in 3,3-amino-9-ethyl carbazole (Sigma Chemical Co.) for 5 to 10 
rain and the reaction was stopped in H20. The ceils were counterstained 
with hematoxyline, mounted with glycerine-gelatine and were then ready 
for microscopy. 
Results 
Polyclonal Antibodies Directed against the Variant 
Portion of the Human CD44 Glycoprotein 
To obtain antibodies directed against the variant portion of 
the human CD44 molecule, we immunized rabbits with a fu- 
Figure  3. Western  blot analysis of several human  cell lines with poly- 
clonal CD44v-specific antibodies. (A) Reaction with anti-DlII. (B) 
Reaction with anti-CD44v (v3 to vl0). Cell lysates were resolved 
on 6%  SDS polyacrylamide. 
Table L Expression of Variant CD44 in Normal 
Human Tissues 
Antibody specificity 
CD44s  CD44v  DIII  DI 
Tissues  (NKI-P1)  (v3-vl0)  (v6,v7)  (v3) 
Lymphohematopoetic 
lymphocytes  + + +  (+)  -  - 
granulocytes  + + +  -  -  - 
monocytes/macrophages  + + +  (+)  -  - 
erythrocytes  + + +  -  -  - 
thrombocytes  .... 
Epithelial tissues 
keratinocytes  + + +  + + +  + +  + + 
mucosa of tonsils and pharynx  + + +  + + +  + +  + 
pancreas 
ducts  + + +  + + +  + +  + 
acini  .... 
thyroid  + + +  + + +  + +  - 
liver 
hepatocytes  .... 
bile ducts  .... 
bronchus  + + +  + + +  + +  - 
kidney tubules  .... 
small intestine 
crypts  +  (+)  (+)  - 
villi  .... 
large intestine 
crypt base  +  (+)  (+)  - 
crypts  .... 
Other 
fibroblasts  + + +  -  -  - 
endothelium  +  -  -  - 
smooth muscle  + + +  -  -  - 
skeletal  muscle  .... 
brain 
neurons  .... 
astrocytes  + + +  -  -  - 
rnicroglia  + + +  +  +  - 
(+), very weak/equivocal;  +, weak;  ++, moderate;  +++,  strong 
sion protein composed of variant exon-encoded sequences 
v3 to vl0 of human CD44 and the bacterial glutathione-S- 
transferase  (Fig.  1;  and  see  Materials  and Methods).  Im- 
munoreactive  rabbit  antiserum  was  purified  stepwise  by 
affinity chromatography  (Material and Methods).  In West- 
ern blots, fusion proteins with all exon sequences found in 
keratinocytes (v3 to vl0),  as well as proteins composed of 
only  exon  v3  sequence  (DI)  and  of exons  v6,  v7  (DIII), 
respectively, were detected by the antibodies (Fig. 2  C, lanes 
1-3). Antibodies with specificity against the v3 sequence and 
the v6/v7 sequence, respectively, were purified using the ap- 
propriate affinity columns (Materials and Methods).  Their 
specificity is demonstrated by Western blot analysis (Fig. 2, 
A  and B,  lanes 1-3). 
To prove that the antibodies react also with variant CD44 
protein expressed  on cells,  we prepared  cell extracts  from 
several human cell lines and subjected these to Western blot 
analysis.  The  cells  were  chosen  on the  basis  of previous 
Northern blotting data (Hofmann et al.,  1991). The immor- 
talized keratinocyte cell lines HaCat and HPKII expressed 
a  CD44v-RNA  species  containing sequences complemen- 
tary to exons v3 to vl0 (Hofmann et al.,  1991).  The poly- 
clonal rabbit antiserum affinity-purified on CD44v v3 to vl0 
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ant  CIM4  on normal  tonsil 
and skin: (a and b) serial sec- 
tions of tonsil,  stained with 
mAb NKI-P1 against the stan- 
dard part  of CIM4  (a),  and 
with antibodies  against  variant 
CD44 (v3-vl0) (b). GC, ger- 
minal center; M, mantle zone; 
E, epithelium. (c and d) Serial 
sections of skin, stained with 
mAb NKI-P1 against standard 
part of  CIM4 (c), and with an- 
tibodies against variant CIM4 
DI~ (v6/7) (d). While the epi- 
tope on the standard part of 
CD44 detected by NKI-P1 is 
expressed on a variety of cell 
types  including epithelium, 
lymphocytes, fibroblasts and 
blood vessels, expression of 
variant CD44 is limited to epi- 
thelium. Counterstain hema- 
toxilyne. Bar, 100/zm. 
stained proteins from HaCat cell extracts with apparent mo- 
lecular weights of 110, 130, 180, and 230 kD, and a major 
protein of ~130 kD from HPKII-extracts (Fig. 3 B). By im- 
mune precipitation with the polyclonal antiserum and subse- 
quent Western analysis with a mAb directed against CD44s, 
identity of the proteins with CIM4 variants was confirmed 
(not shown). The colon carcinoma cell line HT29 expressed 
one major RNA species that hybridized with exons v8 to vl0 
(Hofmann et al.,  1991). The polyclonal antibody stained a 
single protein band with the apparent molecular weight of 
180 kD in the Western blot analysis (Fig. 3 B). This could be 
taken as an indication that the polyclonal serum reacts also 
with sequences derived from exons v8 to vl0. The CD44v- 
negative cell line MeWo (Hofmann et al., 1991) did not react 
with the antisera. Glutathione transferase specific antibodies 
that were purified similarly to CD44v antibodies from the 
same rabbit antiserum showed no staining with either protein 
extract tested (not shown). The anti-DlIl (v6 and v7) antibod- 
ies only recognized a protein of 130 kD in both HPKII and 
HaCat cells (Fig.  3 A).  Possibly this (these) epitope(s)  is 
(are) masked on the larger proteins. With anti-DIII there was 
no reaction with HT29 or MeWo cell extracts. 
Expression of CD44 and CD44 Variant Proteins on 
Human Cells and 1Issues 
The cell and tissue distribution of CIM4 and CIM4 variant 
proteins was assessed in immunohistochemical  studies using 
mAb NKI-P1 against the standard part of CD44 and the anti- 
bodies against the variant portion of CD44.  It should be 
noted that NKI-P1  also recognizes the variants of CD44 as 
they contain the complete standard sequences, and that im- 
munostaining indicates accessibility of epitopes, not neces- 
sarily synthesis or absence of  the protein. In accordance with 
previous observations (Pals et al., 1989a), CD44 as detected 
by mAb NKI-P1  was found to be expressed on a variety of 
normal cells and tissues (Table I; and Fig. 4). In the lympho- 
hematopoetic system high level expression of the NKI-P1 
epitope was observed on B and T lymphocytes (with the ex- 
ception of germinal center B cells and cortical thymocytes), 
on macrophages, including alveolar macrophages of  the lung 
and Kuppfer cells of  the liver, on dendritic cells, and on gran- 
ulocytes and erythrocytes. In epithelial tissues,  the squa- 
mous epithelia of  the epidermis, tonsils and pharynx, and the 
glandular epithelia of the salivary glands, intralobular pan- 
creatic ducts and of the thyroid stained positive, whereas he- 
patocytes, bile duct epithelium and kidney tubules did not 
express CD44. In the epithelia of the small and large intes- 
tine weak staining was observed at the base of the crypts. 
Furthermore, we observed CD44 expression in fibroblasts, 
endothelial cells, and smooth muscle cells in many tissues. 
In brain, astrocytes and microglia were positive. Similar tis- 
sue distribution of CIM4 has been found in the rat (Wirth, 
K., R. Arch, C. Somasundaram, M. Hofmann, P. Herrlich, 
S. Matzku, and M. Z611er, manuscript submitted for publi- 
cation). 
Compared  to  the  wide  tissue  distribution  of standard 
CD44 as detected by NKI-P1,  the expression of epitopes of 
the splice variant domains was much more restricted. Anti- 
bodies raised against the fusion protein containing all variant 
domains from v3 to vl0, as well as those against v6/v7 (DIH) 
Table 11. Expression of CD44 and Variant CD44 in 
Colorectal Neoplasia 
Antibody specificity  (No+/No. tested) 
CD44  CD44v  DIII  DI 
(NKI-P1)  (v3-vl0)  (v6,v7)  (v3) 
Adcnornatous polyps  17/17"  16/17"  14/17"  0/17 
Adenocarcinoma  17/17  17/17  16/17  0/17 
Metastasis  8/8  8/8  8/8  0/8 
* Focal expression  in areas showing moderate or severe dysplasia. 
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riant  CD44  in  colorectal 
neoplasia.  (a)  Normal  colon 
mucosa stained for CIM4 (v3- 
vl0); no unequivocal staining 
is observed. (b) Expression of 
variant CD44  (v3-vl0) in an 
adenomatous polyp.  Expres- 
sion is clearly related to the 
parts  of the tumor with  ad- 
vanced dysplasia. (c) Detail of 
b.  (d)  Expression  of variant 
CD44 Dill (v6 and v7) in an 
invasive  colorectal carcinoma. 
(b) or (a, c, and d), counter- 
stain hematoxilyne. Bars, (b) 
400  #m;  and  (a,  c,  and  d) 
100 ~m. 
strongly stained epidermal keratinocytes, tonsiUar and pha- 
ryngeal epithelium, bronchus and thyroid gland (Table I, and 
Fig.  4).  High level expression was  also observed in pan- 
creatic epithelium, which seems at variance with previous 
studies on rat pancreas (Wirth, K., R. Arch, C.  Somasun- 
daram, M. Hofmarm, P. Herrlich, S. Matzku, and M. Z611er, 
manuscript submitted for publication). At the base of intesti- 
nal crypts very weak signals were found. Microglia cells in 
the brain were slightly positive. Expression of epitope DI 
(v3) was limited to epidermal keratinocytes, the mucosa of 
tonsils and pharynx, and pancreatic ducts. CD44 variant epi- 
topes were not found on numerous other tissues including all 
mesenchymal ceils (fibroblasts, smooth, and striated muscle 
endothelium).  CIM4v  expression  thus  is  limited  to  few 
differentiation pathways. We note, however, that expression 
of an epitope does not imply that the CD44  variants ex- 
pressed are identical. 
Expression of CD44 and CD44 
Variant in Adenomatous Polyps and 
Colorectal Carcinomas 
As mentioned in the previous section, specimens of  histolog- 
ically normal colon mucosa showed weak expression of stan- 
dard CD44  on epithelial cells localized at the base of the 
crypts, while staining with antibodies to CD44v (v3 to vl0) 
or Dill (v6 and v7) was either very weak or undetectable. In 
marked contrast to this restricted expression of CD44 (stan- 
dard) in the normal colon, all invasive colon carcinomas and 
carcinoma metastases expressed CD44 at moderate to high 
levels. These tumors were stained by NKI-P1, CD44v (v3 to 
vl0) and v6/v7-specific antibodies. In most carcinomas, the 
majority of tumor cells were positive for the NKI-P1 and v3 
to vl0 epitopes, but considerable intratumor heterogeneity 
in staining intensity was  generally observed. Importantly, 
areas positive for v3 to vl0 antibodies were present in all car- 
cinomas, and all (but one) showed staining with DIII (v6, 
v7)-specific antibodies (Table II; and see Fig.  5). 
Five of the colorectal carcinomas that were positive for 
CIM4v expression upon histological staining with antibod- 
ies were examined by Western blot analysis (Fig.  6,  lanes 
6-10). Arrows indicate prominent bands that react specifi- 
cally  with  antibodies  against  CD44v  (v3  to  vl0).  The 
unspecific band at '~120 kD will be discussed below. The 
different tumor  samples  show  pronounced differences in 
specific staining  intensity. These differences are in agree- 
ment  with  those  found by  immunohistochemical  surface 
staining, both with respect to number of positive cells and 
intensity of CD44v expression, e.g., in tumors examined in 
Fig. 6, lanes 9 and 10, 90 % of cells were strongly positive 
for CD44v expression, whereas in those used in lane 6 and 
8  only 30 to  50%  of the cells were CD44v positive and 
Figure 6. Western blot analysis of several human cell lines and colo- 
rectal carcinomas with polyclonal CEM4v (v3 to vlO) specific anti- 
bodies. In lane I to 4 extracts from the following colorectal carci- 
noma cell lines were used: SW 480 (1), SW 620 (2), Colo 205 (3), 
and Colo 320 (4). The extract used for lane 5 was obtained from 
the melanoma cell line MeWo. In lanes 6 to 10 extracts obtained 
from five different colorectal carcinomas were applied. Proteins 
were resolved on 6% SDS polyacrylamide. 
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derived from colorectal carcinomas differ in their expression 
of CD44v (Fig.  6, lanes 1-4). One cell line apparently  ex- 
presses proteins similar  to those found in colorectal carci- 
nomas (lane 3), the others are negative for CIM4v. The two 
cell lines used in lanes 1 and 2 (SW480 and SW620) had been 
examined  for RNA expression previously and  were also 
negative for CD44v expression in this test (Hofmann et al., 
1991). The cell line MeWo (Fig. 6, lane 5) was used as nega- 
tive control (see also Fig. 3) to identify unspecific  staining. 
For  one  carcinoma  (Dukes  C)  and  two  lymph  node 
metastases it was possible to elucidate the structure of the 
variant  portion of the CD44v-RNA expressed. RNA pre- 
pared  from these samples was subjected to reverse tran- 
scription-PCR-amplification  using primers corresponding to 
sequences within either the v6 or v8 region and the 3' or the 
5' standard region.  The data are compatible with expression 
of a single major RNA species comprising sequences v6 to 
vl0 but lacking  v3 to v5 (data not shown). 
Interestingly,  CD44 was also expressed on adenomatous 
polyps which represent precursor lesions of colon carci- 
noma. In addition to staining with NKI-P1, these adenomas 
showed focal staining with CD44v v3 to vl0-specific as well 
as DHI (v6 and v7)-specific antibodies.  Expression of these 
variants in the polyps was clearly associated with areas of  ei- 
ther moderate or severe dysplasia, and hence with morpho- 
logical evidence of tumor progression within the adenomas. 
We observed no correlation between staining  for CD44 
v3-vl0 or DHI (v6 and v7) and overexpression  of p53 as de- 
tected by mAb pAbl801. Both colocalization  and differential 
localization  were observed in adenomas  and carcinomas 
which showed an overall  p53 positivity of 50 and  18%, 
respectively. 
Discussion 
Expression of CD44 determinants  has recently been linked 
to tumor dissemination in several systems including human 
non-Hodgkin lymphomas (Pals et al.,  1989b; Horst et al., 
1990; Jalkanen et al., 1990) and rat adenocarcinomas (Gtin- 
thert et al., 1991). In the latter system, a new variant of the 
CD44 molecule generated by alternative  splicing  was shown 
to be causally involved in metastasis formation.  Using  anti- 
bodies raised against fusion proteins of human homologues 
of the variant portion of CD44, we now demonstrate expres- 
sion of variants of the CD44 glycoprotein family in several 
normal human tissues.  Furthermore,  we show that  CD44 
variant  sequences, which in the rat confer metastatic be- 
havior,  are overexpressed in human colorectal carcinomas 
and  carcinoma  metastases,  and,  to  a  lesser  extent,  in 
adenomatous polyps. 
While biochemical studies indicated the presence of  heter- 
ogeneous sets of CD44 glycoproteins on many cell types 
(Jalk~-en et aL,  1988;  Pals et al.,  1989a;  Picker et al., 
1989), and several CD44 RNA splice variants have recently 
been identified  (Stamenkovic  et al.,  1991; Gfinthert et al., 
1991; Hofmann et al.,  1991; Dougherty et al., 1991; Brown 
et al.,  1991; Shtiveiman  and  Bishop,  1991), our present 
study is the first to document differential  expression at the 
protein level of variant domains in humans.  In comparison 
with the abundance of standard CD44, these variants  show 
a very restricted distribution in normal human tissues. Thus, 
whereas many epithelial  as well as non-epithelial  cells ex- 
press high levels of standard CD44, variant CD44 glycopro- 
reins are found, at detectable levels, at only a subset of epi- 
thelial  cells (Table I). 
The causal role of variant CD44 glycoproteins in the lym- 
phatic spread of carcinomas in the rat prompted us to study 
expression of CD44 variants in spontaneous human tumors. 
For this study we chose colorectal neoplasia,  since in this tu- 
mor type individual stages of the multi-stage  carcinogenesis 
process can be morphologically distinguished.  From normal 
mucosa  through  local  hyperplasia  and  various  adenoma 
stages to carcinoma, morphological phenotypes have been 
related to genetic changes  (reviewed by Fearon and Vogel- 
stein,  1990). Here we observe that variant CD44 glycopro- 
reins, which in the rat are associated with metastatic spread, 
are strongly  overexpressed in colorectal neoplasia.  Thus, 
whereas in the normal colon CD44 variant epitope expres- 
sion is very weak and restricted to epithelial cells at the base 
of the crypts, a moderate to strong diffuse expression was 
found in most of the invasive  carcinomas and carcinoma 
metastases tested.  (Table H; and Fig.  5).  In adenomatous 
polyps, focal expression of  variant CD44 epitopes was found 
(Fig. 5). This overexpression  was clearly related to the de- 
gree of dysplasla within the adenomas and hence to progres- 
sion within these limits. 
The progressive accumulation of genetic changes in multi- 
step carcinogenesis  is thought to be caused by mutation and 
clonal  selection.  Changes  at  chromosomes  5q  (putative 
gene:  APC and MMC),  12p  (RAS),  17p (p53),  and  18q 
(DCC) (reviewed by Fearon and Vogelstein, 1990) appear to 
produce growth advantages.  DCC interestingly  codes for a 
putative adhesion protein  (Fearon et aL,  1990).  Loss of 
adhesive functions  and gain of new adhesive functions  are 
likely to be important in the development of metastatic can- 
cer.  The CD44 variants  could be such new adhesion  pro- 
teins. Overexpression in colorectal epithelial cells could lead 
to altered adhesion and  to growth-promoting  signals  as- 
sociated with adhesion.  If we assume, as is supported by the 
data obtained in rats, that the CD44 variants are part of the 
mechanism of metastasis formation,  it is likely that CD44v 
expression is not the only property required. All relevant fea- 
tures need to be assembled to cause metastatic spread but 
the order of their  acquirement  may not matter.  Further, 
metastatic properties may develop independently of cellular 
transformation.  Metastasis formation depends, however, on 
the growth potential  established by transformation.  In colo- 
rectal cancer, the acquisition of CD44v seems to be an early 
event which precedes overexpression  of p53.  We should, 
however, be cautious as the possibility exists that the variant 
proteins expressed on polyps and those on metastases are not 
identic~. 
Interestingly,  colon carcinoma cell lines  differ dramati- 
cally with respect to CD44 variant expression.  Only one out 
of five expresses proteins that migrate similarly  in SDS-gel 
electrophoresis to those expressed in tumors. Another colon 
carcinoma cell line, HT29, carries a prominent CD44 variant 
with only the exons v8 to vl0 (Stamenkovic et al., 1991; Hof- 
mann et al.,  1991) whereas three others were negative for 
CD44v. Primary colon carcinomas and metastases synthe- 
size variants that contain exons v6 and v7 according to stain- 
ing with the affinity.purified antibody. PCR analysis of three 
samples examined  indicate the presence of v6 through  vlO 
sequences in CD44v. 
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study, suggests a role for variant CD44 glycoproteins in cer- 
tain normal epithelial differentiation pathways, while appar- 
ent deregulation and overexpression in colorectal neoplasia 
is  consistent  with a  possible  role in metastatic  behavior, 
analogous to that found in the rat (Gfinthert et al., 1991).  It 
will be important to determine whether this overexpression 
in  colon  tumors  is  regulatory  or  is  mutationally  fixed. 
Clearly,  overexpression can  serve as a tumor progression 
marker in human cancer.  In this context, it is of interest that 
the genetic control of susceptibility to colon carcinoma in 
mice  has  been  linked to  the  chromosomal  region  of the 
CD44 gene (Moen et al.,  1992). 
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